Privacy Statement - Processing of personal data for the survey of carbapenem- and/or colistin-resistant Enterobacteriaceae
Data are processed for the conduct of the carbapenem- and/or colistin-resistant Enterobacteriaceae (CCRE) survey as part of molecular surveillance of antimicrobial resistant pathogens according to a protocol. For the CCRE survey bacterial isolates (carbapenem and/or colistin-resistant Enterobacteriaceae and susceptible control isolates) and related patient data are collected in hospitals in 37 countries with the aim to determine transmission pathways and improve control measures.
Rapid risk assessment: Regional outbreak of New Delhi metallo-betalactamase-producing carbapenem-resistant Enterobacteriaceae, Italy, 2018–2019
A large outbreak of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE) has been reported from the Tuscany region in Italy. Between November 2018 and May 2019, seven Tuscan hospitals notified a total of 350 cases.
ECDC country visit to Norway to discuss antimicrobial resistance issues
An ECDC country visit team conducted an assessment mission during the period 12–16 March 2018 to discuss antimicrobial resistance (AMR) issues in Norway. The overall objective of the mission was to provide an observation-based assessment of the situation in Norway regarding prevention and control of AMR through prudent use of antibiotics and infection control.
Worsening epidemiological situation of carbapenemase-producing enterobacteriaceae in europe, assessment by national experts from 37 countries, july 2018
Brolund, A., Lagerqvist, N., Byfors, S., Struelens, M.J., Monnet, D.L., Albiger, B., Kohlenberg, A.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: Guidance from the European Centre for Disease Prevention and Control
Magiorakos, A.P., Burns, K., Rodríguez Baño, J., Borg, M., Daikos, G., Dumpis, U., Lucet, J.C., Moro, M.L., Tacconelli, E., Simonsen, G.S., Szilágyi, E., Voss, A., Weber, J.T.
Rapid Risk Assessment: Plasmid-mediated colistin resistance in Enterobacteriaceae, 15 June 2016
This document assesses the risk for patients and healthcare systems in the EU/EEA due to the global mcr-1 plasmid-mediated gene epidemic.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
US CDC report on antibiotic resistance threats in the United States, 2013
Antimicrobial resistance represent a serious threat to public health and patient safety and is a worldwide problem. Each year, in the European Union (EU) at least 25 000 patients die of infections with multidrug-resistant bacteria.
US CDC guidance for control of carbapenem-resistant Enterobacteriaceae (CRE) – 2012 CRE toolkitArchived
Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are highly resistant to antibiotics, leaving only a few options for treatment of infected patients, and thus represent a serious threat to public health.